
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) – Analysts at HC Wainwright issued their Q1 2027 earnings estimates for Enanta Pharmaceuticals in a research report issued on Tuesday, November 17th. HC Wainwright analyst B. Folkes anticipates that the biotechnology company will post earnings of ($0.49) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($2.24) per share. HC Wainwright also issued estimates for Enanta Pharmaceuticals’ Q2 2027 earnings at ($0.53) EPS, Q3 2027 earnings at ($0.55) EPS, Q4 2027 earnings at ($0.57) EPS, FY2027 earnings at ($2.14) EPS, FY2028 earnings at ($2.67) EPS, FY2029 earnings at ($1.95) EPS and FY2030 earnings at ($1.62) EPS.
Other equities analysts have also recently issued reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Thursday, October 15th. JPMorgan Chase & Co. lowered their target price on Enanta Pharmaceuticals from $19.00 to $17.00 and set an “overweight” rating for the company in a research note on Friday. Finally, Wall Street Zen lowered Enanta Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $19.00.
Enanta Pharmaceuticals Price Performance
Enanta Pharmaceuticals stock opened at $7.62 on Thursday. Enanta Pharmaceuticals has a 12-month low of $7.56 and a 12-month high of $17.15. The company has a market capitalization of $221.89 million, a price-to-earnings ratio of -3.24 and a beta of 0.75. The firm’s fifty day moving average price is $11.48 and its 200 day moving average price is $12.97.
Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) last announced its earnings results on Monday, November 16th. The biotechnology company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.09). The firm had revenue of $12.87 million during the quarter, compared to analysts’ expectations of $14.62 million. Enanta Pharmaceuticals had a negative net margin of 108.33% and a negative return on equity of 59.48%.
Hedge Funds Weigh In On Enanta Pharmaceuticals
Several institutional investors and hedge funds have recently made changes to their positions in the business. Janus Henderson Group PLC grew its holdings in Enanta Pharmaceuticals by 1.5% during the 1st quarter. Janus Henderson Group PLC now owns 3,784,055 shares of the biotechnology company’s stock worth $47,717,000 after acquiring an additional 54,396 shares in the last quarter. Jupiter Topco LLC acquired a new stake in shares of Enanta Pharmaceuticals in the 2nd quarter valued at about $53,252,000. BlackRock Inc. acquired a new stake in shares of Enanta Pharmaceuticals in the 2nd quarter valued at about $47,304,000. ADAR1 Capital Management LLC acquired a new stake in shares of Enanta Pharmaceuticals in the 2nd quarter valued at about $19,603,000. Finally, Spruce Street Capital LP acquired a new stake in shares of Enanta Pharmaceuticals in the 2nd quarter valued at about $15,873,698. 94.99% of the stock is currently owned by hedge funds and other institutional investors.
Recent Enanta Pharmaceuticals Headlines
Here are a few of the latest headlines about ENTA:
- Positive Sentiment: HC Wainwright maintained its Buy rating and $20 price target, while raising its FY2027–FY2030 earnings estimates to reflect smaller projected losses. This signals improved longer-term expectations, though the forecasts still show losses. MarketBeat report
- Neutral Sentiment: JPMorgan cut its price target to $17 from $19 but kept an Overweight rating. The lower target is a negative revision, while the rating and implied upside from the cited $7.62 share price remain supportive.
- Negative Sentiment: Enanta’s latest reported quarter missed expectations: its loss per share was wider than analysts forecast, and revenue came in below estimates. The results may weigh on sentiment amid the analyst updates. MarketBeat earnings information
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc. is a biotechnology company based in Watertown, Massachusetts, that discovers and develops small-molecule medicines. Its research has focused on infectious diseases and inflammatory conditions, including respiratory syncytial virus (RSV), hepatitis B and immunology. Enanta’s work with AbbVie contributed to the discovery of glecaprevir, an antiviral used with pibrentasvir in the hepatitis C treatment Mavyret. The collaboration reflects the company’s history of applying its drug-discovery expertise to antiviral therapies.
Featured Articles
- Five stocks we like better than Enanta Pharmaceuticals
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
